Post «Healx raises $56M Series B to use AI to find treatments for rare diseases» in blog Прогноз погоды

People

John Smith

John Smith, 48

Joined: 28 January 2014

Interests: No data

Jonnathan Coleman

Jonnathan Coleman, 32

Joined: 18 June 2014

About myself: You may say I'm a dreamer

Interests: Snowboarding, Cycling, Beer

Andrey II

Andrey II, 41

Joined: 08 January 2014

Interests: No data

David

David

Joined: 05 August 2014

Interests: No data

David Markham

David Markham, 65

Joined: 13 November 2014

Interests: No data

Michelle Li

Michelle Li, 41

Joined: 13 August 2014

Interests: No data

Max Almenas

Max Almenas, 53

Joined: 10 August 2014

Interests: No data

29Jan

29Jan, 31

Joined: 29 January 2014

Interests: No data

s82 s82

s82 s82, 26

Joined: 16 April 2014

Interests: No data

Wicca

Wicca, 36

Joined: 18 June 2014

Interests: No data

Phebe Paul

Phebe Paul, 26

Joined: 08 September 2014

Interests: No data

Артем Ступаков

Артем Ступаков, 93

Joined: 29 January 2014

About myself: Радуюсь жизни!

Interests: No data

sergei jkovlev

sergei jkovlev, 59

Joined: 03 November 2019

Interests: музыка, кино, автомобили

Алексей Гено

Алексей Гено, 8

Joined: 25 June 2015

About myself: Хай

Interests: Интерес1daasdfasf, http://apple.com

ivanov5056 Ivanov

ivanov5056 Ivanov, 69

Joined: 20 July 2019

Interests: No data



Healx raises $56M Series B to use AI to find treatments for rare diseases

10:00 | 16 October expand

Healx raises $56M Series B to use AI to find treatments for rare diseases

Healx, a Cambridge, U.K.-based startup using AI to help discover new treatments for rare diseases, has raised $56 million in Series B funding.

Leading the round is London-base VC firm Atomico, with participation by Intel Capital, Global Brain and btov Partners. All previous investors, including Balderton Capital, Amadeus Capital Partners, and Jonathan Milner have also followed on.

Healx says the new financing will be used to develop the company’s “therapeutic pipeline” and to launch its global Rare Treatment Accelerator programme, which will partner with patient groups in an attempt to make rare desease drug discovery much more efficient.

More broadly, the aim is to discover new treatments and move them towards clinic “within 24 months,” which is significantly faster than the status quo. Meanwhile, many rare conditions aren’t currently the focus of new treatments at all.

“There are over 7,000 rare diseases affecting 400 million people worldwide (50% of these are children). Of these diseases, 95% still lack an approved treatment today,” Healx co-founder and CEO Dr Tim Guilliams tells TechCrunch.

“The traditional model of discovery and clinical development of new medicines is very expensive in terms of costs, timelines and efficacy. To bring a new drug to market typically costs $2-3 billion, takes 12-14 years to develop and has a 95% failure rate”.

Specifically, Guilliams says that the current model doesn’t work for diseases which have a small patient population as the return on investment from drug sales simply won’t work with the discovery and development costs being so high. What’s needed is a “radical change of course” by using AI to discover alternative uses for existing drugs.

“By focusing on approved drugs and harnessing the power of AI we’ve been able to make the rare disease drug discovery process a faster and more efficient one,” he claims. “We’ve since made it our mission to progress 100 rare disease treatments towards the clinic by 2025”.

Of course, applying AI technology to drug discovery isn’t unique to Healx and nor are the challenges in doing so. BenevolentAI, for example, has grabbed lots of headlines, most recently reportedly having its valuation cut. However, Guilliams says Healx is taking a different approach to other companies in the space, which also includes Recursion Pharmaceuticals and Insilico Medicine.

“Our focus and approach is quite different. We focus on rare genetic diseases and have the world’s leading biomedical knowledge graph for rare diseases… [and] we don’t develop new molecules, we maximise the value of already-approved drugs”.

In addition, Guilliams says that Healx’s technology is data-driven and “hypothesis-free,” which is very different from traditional target-based drug discovery. “We are able to predict drug combinations and translate them very fast in the clinic… [and] we work extremely closely with patient groups, as strategic partners and disease experts,” he adds.

It’s also worth mentioning that Healx co-founder, Dr David Brown, has invented several drugs that have made it to market (including being one of Viagra’s inventors). These have turned over $40 billion in revenue, apparently. “We know how to do this,” says Guilliams.

Healx claims to have validated its innovative model with the FRAXA Research Foundation. “Fragile X syndrome” is the leading genetic cause of autism and I’m told there are currently no approved treatments for the disease. That could be about to change with Healx and FRAXA set to soon launch early clinical trials to test multiple treatment combinations. Further clinical programmes for other rare diseases will begin later in 2020.

IrinaH 600x400

Atomico’s Irina Haivas

Meanwhile, I asked Atomico Principle Irina Haivas, who led on behalf of the firm, what attracted her to the investment and how she views the risks associated with backing a company like Healx, given it is trying to find a needle in a haystack (drug discovery) and also needs to commercialise those discoveries. In other words, there are a lot of unknowns and a very long time to market.

“One of the reasons I chose to join Atomico is precisely because they are not afraid to make these sorts of bold, long term bets knowing that if it works then Healx will dramatically improve the lives of 400 million people living with a rare disease,” she tells me.

“Obviously, such ambitious bets also come with a certain degree of risk but I would say that in the case of Healx all the early signs are there that we can use AI to solve this “big search” problem better than humans traditionally did. However, the ultimate proof will be getting treatment to market of course”.

With that said, she also cautions that startups like Healx are creating a new category of companies. That’s because they are neither traditional tech nor traditional biopharma.

“They will need a different framework from an investor perspective, some investors will take time to get comfortable with that,” adds the surgeon-turned-VC.

Healx raises $56M Series B to use AI to find treatments for rare diseases Healx raises $56M Series B to use AI to find treatments for rare diseases Healx raises $56M Series B to use AI to find treatments for rare diseases Healx raises $56M Series B to use AI to find treatments for rare diseases Healx raises $56M Series B to use AI to find treatments for rare diseases Healx raises $56M Series B to use AI to find treatments for rare diseases
Healx raises $56M Series B to use AI to find treatments for rare diseases

 


Read more→

Posted on 16.10.2019 10:00

Comments

To show the previous comments (%s from %s)
Show new comments

Last comments

Walmart retreats from its UK Asda business to hone its focus on competing with Amazon
Peter Short
Good luck
Peter Short

Evolve Foundation launches a $100 million fund to find startups working to relieve human suffering
Peter Short
Money will give hope
Peter Short

Boeing will build DARPA’s XS-1 experimental spaceplane
Peter Short
Great
Peter Short

Is a “robot tax” really an “innovation penalty”?
Peter Short
It need to be taxed also any organic substance ie food than is used as a calorie transfer needs tax…
Peter Short

Twitter Is Testing A Dedicated GIF Button On Mobile
Peter Short
Sounds great Facebook got a button a few years ago
Then it disappeared Twitter needs a bottom maybe…
Peter Short

Apple’s Next iPhone Rumored To Debut On September 9th
Peter Short
Looks like a nice cycle of a round year;)
Peter Short

AncestryDNA And Google’s Calico Team Up To Study Genetic Longevity
Peter Short
I'm still fascinated by DNA though I favour pure chemistry what could be
Offered is for future gen…
Peter Short

U.K. Push For Better Broadband For Startups
Verg Matthews
There has to an email option icon to send to the clowns in MTNL ... the govt of India's service pro…
Verg Matthews

CrunchWeek: Apple Makes Music, Oculus Aims For Mainstream, Twitter CEO Shakeup
Peter Short
Noted Google maybe grooming Twitter as a partner in Social Media but with whistle blowing coming to…
Peter Short

CrunchWeek: Apple Makes Music, Oculus Aims For Mainstream, Twitter CEO Shakeup
Peter Short
Noted Google maybe grooming Twitter as a partner in Social Media but with whistle blowing coming to…
Peter Short


Site search